What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2026-04-15 compared with 2025-03-31 · 46 added, 55 removed, 3 unchanged (97% of the section changed)

MARKET FOR REGISTRANT’S COMMON

EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

Market Information

Our units, ordinary shares and rights are listed

on Nasdaq under the symbols “DMAAU,” “DMAA” and “DMAAR,” respectively.

As of March 28, 2025, there

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

units, ordinary shares and rights are listed on Nasdaq under the symbols “DMAAU,” “DMAA” and “DMAAR,”

respectively.

As of April 15, 2026, there

were 33,717,143 ordinary shares (inclusive of ordinary shares included in our units) issued and outstanding, held by a total of 41 holders

The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of

ordinary shares whose shares are held in the names of various security brokers, dealers, and registered clearing agencies.

Dividend Policy

We have not paid any cash dividends on our ordinary

shares to date and do not intend to pay cash dividends prior to the completion of our initial business combination.

The payment of cash

dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition

subsequent to completion of our initial business combination.

The payment of any cash dividends subsequent to our initial business combination

will be within the discretion of our board of directors at such time.

In addition, our board of directors is not currently contemplating

and does not anticipate declaring any share dividends in the foreseeable future.

Further, if we incur any indebtedness in connection with

our initial business combination, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection

Securities Authorized for Issuance Under

Equity Compensation Plans

Recent Sales of Unregistered Securities;

of Proceeds from Registered Securities

Unregistered Sales

Use of Proceeds

On January 29, 2025, we consummated

our IPO of 20,000,000 Units.

Each Unit consists of one ordinary share and one right to receive one-eighth (1/8) of one Ordinary Share

upon the consummation of an initial business combination.

The Units were sold at an offering price of $10.00 per unit, generating gross

proceeds, before expenses, of $200,000,000.

We granted the underwriters a 45-day option to purchase up to 3,000,000 additional Units to

cover over-allotments, if any.

Simultaneously with the closing of the IPO, we consummated the private placement with Drugs Made In America

Acquisition LLC, our sponsor, of 400,000 Private Placement Units at a price of $10.00 per unit, for $4,000,000.

On February 13, 2025, the underwriters

exercised the over-allotment option in full, and the closing of the issuance and sale of the Over-Allotment Option Units occurred on February

The total aggregate issuance by us of 3,000,000 Over-Allotment Option Units at a price of $10.00 per unit resulted in total

gross proceeds of $30,000,000.

On February 18, 2025, simultaneously with the sale of the Over-Allotment Option Units, we consummated the

private sale of an additional 30,000 Private Placement Units, generating gross proceeds of $300,000.

As of February 18, 2025, a total

of $ 231,150,000 of the net proceeds from the sale of Units in the IPO (including the Over-Allotment Option Units) and the private placement

of the Private Placement Units, were placed in a trust account established for the benefit of the Company’s public shareholders.

The number of record holders was determined from the records of our transfer agent and does not include beneficial owners

of ordinary shares whose shares are held in the names of various security brokers, dealers, and registered clearing agencies.

have not paid any cash dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of our

initial business combination.

The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital

requirements and general financial condition subsequent to completion of our initial business combination.

The payment of any cash dividends

subsequent to our initial business combination will be within the discretion of our board of directors at such time.

In addition, our

board of directors is not currently contemplating and does not anticipate declaring any share dividends in the foreseeable future.

if we incur any indebtedness in connection with our initial business combination, our ability to declare dividends may be limited by

restrictive covenants we may agree to in connection therewith.

Authorized for Issuance Under Equity Compensation Plans

Sales of Unregistered Securities;

Use of Proceeds from Registered Securities

January 29, 2025, we consummated our IPO of 20,000,000 Units.

Each Unit consists of one ordinary share and one right to receive one-eighth

(1/8) of one Ordinary Share upon the consummation of an initial business combination.

The Units were sold at an offering price of $10.00

per unit, generating gross proceeds, before expenses, of $200,000,000.

We granted the underwriters a 45-day option to purchase up to

3,000,000 additional Units to cover over-allotments, if any.

Simultaneously with the closing of the IPO, we consummated the private placement

with Drugs Made In America Acquisition LLC, our sponsor, of 400,000 Private Placement Units at a price of $10.00 per unit, for $4,000,000.

February 13, 2025, the underwriters exercised the over-allotment option in full, and the closing of the issuance and sale of the Over-Allotment

Option Units occurred on February 18, 2025.

The total aggregate issuance by us of 3,000,000 Over-Allotment Option Units at a price of

$10.00 per unit resulted in total gross proceeds of $30,000,000.

On February 18, 2025, simultaneously with the sale of the Over-Allotment

Option Units, we consummated the private sale of an additional 30,000 Private Placement Units, generating gross proceeds of $300,000.

of February 18, 2025, a total of $231,150,000 of the net proceeds from the sale of Units in the IPO (including the Over-Allotment Option

Units) and the private placement of the Private Placement Units, were placed in a trust account established for the benefit of the Company’s

public shareholders.

The funds in the trust account will be invested only in U.S.

government treasury obligations with a maturity of 185 days or less or in

money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S.

treasury obligations and/or held as cash or cash items (including in demand deposit accounts).

For a description of the use

of the proceeds generated in our IPO and the private placement of the Private Placement Units, see Part II, Item 7 ( Management’s

Discussion and Analysis of Financial Condition and Results of Operations ) of this Annual Report on Form 10-K.

There has been no material

change in the planned use of proceeds from the IPO and the private placement of the Private Placement Units as described in the Registration

government treasury obligations with a maturity of

185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only

in direct U.S.

government treasury obligations and/or held as cash or cash items (including in demand deposit accounts).

a description of the use of the proceeds generated in our IPO and the private placement of the Private Placement Units, see Part II,

Item 7 ( Management’s Discussion and Analysis of Financial Condition and Results of Operations ) of this Annual Report on

There has been no material change in the planned use of proceeds from the IPO and the private placement of the Private Placement

Units as described in the Registration Statement.

The specific investments in our trust account may change from time to time.

Purchases of Equity Securities by the Issuer

and Affiliated Purchasers

of Equity Securities by the Issuer and Affiliated Purchasers

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity